|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zeng H, Zheng R, Guo Y, Zhang S, Zou X,
Wang N, Zhang L, Tang J, Chen J, Wei K, et al: Cancer survival in
China, 2003–2005: A population-based study. Int J Cancer.
136:1921–1930. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Moreira AL and Thornton RH: Personalized
medicine for non-small-cell lung cancer: Implications of recent
advances in tissue acquisition for molecular and histologic
testing. Clin Lung Cancer. 13:334–339. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Martin P, Leighl NB, Tsao MS and Shepherd
FA: KRAS mutations as prognostic and predictive markers in
non-small cell lung cancer. J Thorac Oncol. 8:530–542. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Papadimitrakopoulou V: Development of
PI3K/AKT/mTOR pathway inhibitors and their application in
personalized therapy for non-small-cell lung cancer. J Thorac
Oncol. 7:1315–1326. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shepherd FA, Lacas B, Le Teuff G, Hainaut
P, Jänne PA, Pignon JP, Le Chevalier T, Seymour L, Douillard JY,
Graziano S, et al: Pooled analysis of the prognostic and predictive
effects of TP53 comutation status combined with KRAS or EGFR
mutation in early-stage resected non-small-cell lung cancer in four
trials of adjuvant chemotherapy. J Clin Oncol. 35:2018–2027. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Detterbeck FC, Boffa DJ, Kim AW and Tanoue
LT: The eighth edition lung cancer stage classification. Chest.
151:193–203. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lv W, Wei X, Guo R, Liu Q, Zheng Y, Chang
J, Bai T, Li H, Zhang J, Song Z, et al: Noninvasive prenatal
testing for Wilson disease by use of circulating single-molecule
amplification and resequencing technology (cSMART). Clin Chem.
61:172–181. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Watanabe H, Okada M, Kaji Y, Satouchi M,
Sato Y, Yamabe Y, Onaya H, Endo M, Sone M and Arai Y: New response
evaluation criteria in solid tumours-revised RECIST guideline
(version 1.1). Gan To Kagaku Ryoho. 36:2495–2501. 2009.(In
Japanese). PubMed/NCBI
|
|
10
|
Tsim S, O'Dowd CA, Milroy R and Davidson
S: Staging of non-small cell lung cancer (NSCLC): A review. Respir
Med. 104:1767–1774. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cooper WA, O'Toole S, Boyer M, Horvath L
and Mahar A: What's new in non-small cell lung cancer for
pathologists: The importance of accurate subtyping, EGFR mutations
and ALK rearrangements. Pathology. 43:103–115. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mao C, Qiu LX, Liao RY, Du FB, Ding H,
Yang WC, Li J and Chen Q: KRAS mutations and resistance to
EGFR-TKIs treatment in patients with non-small cell lung cancer: A
meta-analysis of 22 studies. Lung Cancer. 69:272–278. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Luo W, Wang H, Xu WJ, et al: Analysis of
KRAS mutation in patients with non- small cell lung cancer.
Guangdong Med J. 35:2025–2028. 2014.(In Chinese).
|
|
14
|
Yi SQ, Zhuang Y, Zhu WD, et al: Analysis
of KRAS gene mutations in non-small cell lung cancer. Zhonghua Lin
Chuan Yi Shi Za Zhi (Electronic Edition). 7:9111–9115. 2013.(In
Chinese).
|
|
15
|
Scheffler M, Bos M, Gardizi M, König K,
Michels S, Fassunke J, Heydt C, Künstlinger H, Ihle M, Ueckeroth F,
et al: PIK3CA mutations in non-small cell lung cancer (NSCLC):
Genetic heterogeneity, prognostic impact and incidence of prior
malignancies. Oncotarget. 6:1315–1326. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liang NX, Liu YX, Liu L and Li SQ:
Co-mutation of PIK3CA and other oncogenes in patients with
non-small cell lung cancer. Med J PUMCH. 6:186–190. 2015.(In
Chinese).
|
|
17
|
Huang CL, Taki T, Adachi M, Konishi T,
Higashiyama M, Kinoshita M, Hadama T and Miyake M: Mutations of p53
and K-ras genes as prognostic factors for non-small cell lung
cancer. Int J Oncol. 12:553–569. 1998.PubMed/NCBI
|
|
18
|
Kato S, Han SY, Liu W, Otsuka K, Shibata
H, Kanamaru R and Ishioka C: Understanding the function-structure
and function-mutation relationships of p53 tumor suppressor protein
by high-resolution missense mutation analysis. Proc Natl Acad Sci
USA. 100:8424–8429. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kris MG, Johnson BE, Berry LD, Kwiatkowski
DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson
SL, Su PF, et al: Using multiplexed assays of oncogenic drivers in
lung cancers to select targeted drugs. Jama. 311:1998–2006. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cancer Genome Atlas Research Network:
Comprehensive molecular profiling of lung adenocarcinoma. Nature.
511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gao J, Chen JQ, Zhang L and Liang ZY:
Relationship between EGFR and KRAS mutations and prognosis in
Chinese patients with non-small cell lung cancer: A mutation
analysis with real-time polymerase chain reaction using scorpion
amplification refractory mutation system. Zhonghua Bing Li Xue Za
Zhi. 41:652–656. 2012.(In Chinese). PubMed/NCBI
|
|
22
|
Kim HR, Ahn JR, Lee JG, Bang DH, Ha SJ,
Hong YK, Kim SM, Nam KC, Rha SY, Soo RA, et al: The impact of
cigarette smoking on the frequency of and qualitative differences
in KRAS mutations in Korean patients with lung adenocarcinoma.
Yonsei Med J. 54:865–874. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li Y, Li Y, Yang T, Wei S, Wang J, Wang M,
Wang Y, Zhou Q, Liu H and Chen J: Clinical significance of EML4-ALK
fusion gene and association with EGFR and KRAS gene mutations in
208 Chinese patients with non-small cell lung cancer. PLoS One.
8:e520932013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang Q, Wang J, Li X, Zhang H, Nong J,
Qin N, Zhang X, Wu Y, Yang X, Lv J and Zhang S: Clinical Analysis
of 107 NSCLC Patients Harboring KRAS Mutation. Zhongguo Fei Ai Za
Zhi. 19:257–262. 2016.(In Chinese). PubMed/NCBI
|
|
25
|
Hu W, Liu Y and Chen J: Concurrent gene
alterations with EGFR mutation and treatment efficacy of EGFR-TKIs
in Chinese patients with non-small cell lung cancer. Oncotarget.
8:250462017.PubMed/NCBI
|
|
26
|
Korpanty GJ, Graham DM, Vincent MD and
Leighl NB: Biomarkers that currently affect clinical practice in
lung cancer: EGFR, ALK, MET, ROS-1, and KRAS. Front Oncol.
4:2042014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Deben C, Van den Bossche J, Van Der Steen
N, Lardon F, Wouters A, de Beeck KO, Hermans C, Jacobs J, Peeters
M, Van Camp G, et al: Deep sequencing of the TP53 gene reveals a
potential risk allele for non-small cell lung cancer and supports
the negative prognostic value of TP53 variants. Tumour Biol.
39:10104283176943272017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vanderlaan PA, Rangachari D, Mockus SM,
Spotlow V, Reddi HV, Malcolm J, Huberman MS, Joseph LJ, Kobayashi
SS and Costa DB: Mutations in TP53, PIK3CA, PTEN and other genes in
EGFR mutated lung cancers: Correlation with clinical outcomes. Lung
Cancer. 106:17–21. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mascaux C, Iannino N, Martin B, Paesmans
M, Berghmans T, Dusart M, Haller A, Lothaire P, Meert AP, Noel S,
et al: The role of RAS oncogene in survival of patients with lung
cancer: A systematic review of the literature with meta-analysis.
Br J Cancer. 92:131–139. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lin EY, Rupani R and Gitlitz BJ: Markers
in lung cancer. Springer. (New York, NY). 2013. View Article : Google Scholar
|
|
31
|
Scoccianti C, Vesin A, Martel G, Olivier
M, Brambilla E, Timsit JF, Tavecchio L, Brambilla C, Field JK and
Hainaut P;: European Early Lung Cancer Consortium: Prognostic value
of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: The
EUELC cohort. Eur Respir J. 40:177–184. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ma X, Rousseau V, Sun H, Lantuejoul S,
Filipits M, Pirker R, Popper H, Mendiboure J, Vataire AL, Le
Chevalier T, et al: Significance of TP53 mutations as predictive
markers of adjuvant cisplatin-based chemotherapy in completely
resected non-small-cell lung cancer. Mol Oncol. 8:555–564. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lee SY, Jeon HS, Hwangbo Y, Jeong JY, Park
JY, Lee EJ, Jin G, Shin KM, Yoo SS, Lee J, et al: The influence of
TP53 mutations on the prognosis of patients with early stage
non-small cell lung cancer may depend on the intratumor
heterogeneity of the mutations. Mol Carcinog. 54:93–101. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mcgowan M, Hoven AS, Lund-Iversen M,
Solberg S, Helland Å, Hirsch FR and Brustugun OT: PIK3CA mutations
as prognostic factor in squamous cell lung carcinoma. Lung Cancer.
103:52–57. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kang S, Bader AG and Vogt PK:
Phosphatidylinositol 3-kinase mutations identified in human cancer
are oncogenic. Proc Natl Acad Sci USA. 102:802–807. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Molina-Vila MA, Bertran-Alamillo J, Gascó
A, Mayo-de-las-Casas C, Sánchez-Ronco M, Pujantell-Pastor L,
Bonanno L, Favaretto AG, Cardona AF, Vergnenègre A, et al:
Nondisruptive p53 mutations are associated with shorter survival in
patients with advanced non-small cell lung cancer. Clin Cancer Res.
20:4647–4659. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Meng D, Yuan M, Li X, Chen L, Yang J, Zhao
X, Ma W and Xin J: Prognostic value of K-RAS mutations in patients
with non-small cell lung cancer: A systematic review with
meta-analysis. Lung Cancer. 81:1–10. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jao K, Tomasini P, Kamel-Reid S and Tsao
MS: Prognostic effect of single versus multiple somatic mutations
in non-small cell lung cancer (NSCLC). J Clin Oncol.
33:75212015.
|
